Multiple myeloma in a young patient

Authors

  • Miguel Ricardo Quetzal Specialist in General Suergery. FACS. Northern Medical Specialty Plaza. Orange Walk, Belize https://orcid.org/0009-0001-8395-0831
  • Jorge Soler González Specialist in Internal Medicine. Northern Medical Plaza. Orange Walk, Belize

DOI:

https://doi.org/10.61997/bjm.v13i1.405

Keywords:

multiple myeloma, protein electrophoresis, osteolytic lesions, treatment

Abstract

Multiple myeloma is a type B blood cancer characterized by clonal proliferation of malignant plasma cells. The median age at diagnosis is 70 years, however, it is rare among younger patients, and less than 0.5% are younger than 30 years. A 33-year-old man, who began with progressive acute kidney injury is presented, accompanied by a severe lower back pain and impossibility to walk. A dorso-lumbar spine CT scan showed an extensive process consisting of multiple osteolytic lesions at T12, L2, ribs, pelvic and proximal femur. Radiology, along with histology, bone marrow aspiration and protein electrophoresis analysis allowed to establish the diagnosis of stage III multiple myeloma, after which the patient received chemotherapy. Despite the rarity of multiple myeloma among young patients, this diagnosis should be evoked when clinical, biological and radiological signs are in favour. There appears to be no difference between younger and older patients in disease presentation, although longer survival was reported among younger patients.

Downloads

Download data is not yet available.

References

Kyle RA. Rajkumar SV. Multiple myeloma. Blood. 2008; 111(6): 2962–72. Available at: https://doi.org/10.1182/blood-2007-10-078022 DOI: https://doi.org/10.1182/blood-2007-10-078022

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11): 1046-60. Available at: https://www.nejm.org/doi/full/10.1056/NEJMra1011442

Man HV, Dung PC. A case of multiple myeloma in a 17-year-old girl treated with autologous hematopoietic stem cell transplantation (ASCT). Am J Case Rep. 2019; 20: 1623-9. Available at: https://doi.org/10.12659/AJCR.917670 DOI: https://doi.org/10.12659/AJCR.917670

Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016; 1364(1): 32-51. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806534/

Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016; 43(6):676-81. Available at: http://doi.org/10.1053/j.seminoncol.2016.11.004 DOI: https://doi.org/10.1053/j.seminoncol.2016.11.004

Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, et al. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Curr Oncol. 2021; 28(1):640-60. Available at: https://doi.org/10.3390%2Fcurroncol28010063 DOI: https://doi.org/10.3390/curroncol28010063

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. Available at: https://doi.org/10.1056/nejmra1011442 DOI: https://doi.org/10.1056/NEJMra1011442

Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016; 1364(1):32-51. Available at: http://doi.org/10.1111/nyas.13038 DOI: https://doi.org/10.1111/nyas.13038

Koshiaris C, Van den Bruel A, Oke JL, Nicholson BD, Shephard E, Braddick M, et al. Early detection of multiple myeloma in primary care using blood tests: a case-control study in primary care. Br J Gen Pract. 2018; 68(674):e586-e593. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104875/ DOI: https://doi.org/10.3399/bjgp18X698357

Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O. Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn. 2011; 11(6):593-603. Available at: http://doi.org/10.1586/erm.11.44 DOI: https://doi.org/10.1586/erm.11.44

Valković T, Gačić V, Ivandić J, Petrov B, Dobrila-Dintinjana R, Dadić-Hero E, et al. Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors. Turk J Haematol. 2015; 32(3):234-42. http://doi.org/10.4274/tjh.2013.0173 DOI: https://doi.org/10.4274/tjh.2013.0173

Usha, Agarwal N, Kumar P, Rai M, Singh RG, Seth M, Saraf SK. Myeloma in young age. Indian J Pathol Microbiol. 2005; 48(3):314-7. Available at: https://pubmed.ncbi.nlm.nih.gov/16761740/

Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med. 1996; 156:1463–68. Available at: http://doi.org/10.1001/archinte.1996.00440120125014 DOI: https://doi.org/10.1001/archinte.156.13.1463

Miceli TS, Colson K, Faiman BM, Miller K, Tariman JD; International Myeloma Foundation Nurse Leadership Board. Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs. 2011; 15 Suppl(0):9-23. Available at: http://doi.org/10.1188/11.S1.CJON.9-23 DOI: https://doi.org/10.1188/11.S1.CJON.9-23

Gastelum ZN, Biggs DM, Scott A. Multiple Myeloma Presenting as Acute Renal Failure in the Absence of Other Characteristic Features. Cureus. 2017; 9(9):e1703. Available at: http://doi.org/10.7759/cureus.1703 DOI: https://doi.org/10.7759/cureus.1703

Coluzzi F, Rolke R, Mercadante S. Pain management in patients with multiple myeloma: an pdate. Cancers (Basel). 2019; 11(12):2037. Available at: http://doi.org/10.3390/cancers11122037 DOI: https://doi.org/10.3390/cancers11122037

Downloads

Published

03-02-2024

How to Cite

Quetzal, M. R., & Soler González, J. (2024). Multiple myeloma in a young patient. Belize Journal of Medicine, 13(1). https://doi.org/10.61997/bjm.v13i1.405

Issue

Section

Case Reports